The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...

On September 26, the U.S. Food and Drug Administration (FDA) approved a drug called Cobenfy to treat schizophrenia. Cobenfy is a combination of xanomeline and trospium chloride that has a novel ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

fuelled by robust pipeline progress and the US Food and Drug Administration (FDA) approval of its antipsychotic drug Cobenfy for the treatment of schizophrenia in September 2024. Cobenfy is ...

Lastly, we are pleased with the progress of our portfolio as Voranigo and Cobenfy were recently approved by the FDA. Based on our robust deal pipeline, our leading position as the partner of ...

Lastly, we are pleased with the progress of our portfolio as Voranigo and Cobenfy were recently approved by the FDA. Based on our robust deal pipeline, our leading position as the partner of choice in ...

However, this came as good news for investors in AbbVie’s peer Bristol Myers Squibb (NYSE:BMY) as the company recently secured the U.S. FDA approval for its schizophrenia drug Cobenfy ...